Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials

The objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6-month or a 3–8 -y interval between two HPV vaccine doses. The results from two clinical trials, conducted by the same team in the same region, with serological assays performed at the same laboratory usi...

Full description

Bibliographic Details
Main Authors: Vladimir Gilca, Chantal Sauvageau, Gitika Panicker, Gaston De Serres, John Schiller, Manale Ouakki, Elisabeth R. Unger
Format: Article
Language:English
Published: Taylor & Francis Group 2019-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:http://dx.doi.org/10.1080/21645515.2019.1605278
_version_ 1797633744215998464
author Vladimir Gilca
Chantal Sauvageau
Gitika Panicker
Gaston De Serres
John Schiller
Manale Ouakki
Elisabeth R. Unger
author_facet Vladimir Gilca
Chantal Sauvageau
Gitika Panicker
Gaston De Serres
John Schiller
Manale Ouakki
Elisabeth R. Unger
author_sort Vladimir Gilca
collection DOAJ
description The objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6-month or a 3–8 -y interval between two HPV vaccine doses. The results from two clinical trials, conducted by the same team in the same region, with serological assays performed at the same laboratory using the same ELISA methodology were compared. In the first study, 173 9–10-y-old girls and boys received two doses of 9vHPV vaccine at a 6-month interval; in the second study, 31 girls vaccinated with one dose of 4vHPV at the age of 9–14 y received a dose of 9vHPV 3–8 y later (mean 5.4 y). In both studies, blood samples were collected before and 1 month post second dose. Despite large differences in the time since the first dose, all subjects (100%) were seropositive to the common 4 HPV types (6, 11, 16 and 18) to both vaccines, with comparable GMTs and titer distributions before the second dose. One month post second dose, the GMTs increased 40–91-fold for those with a 6-month interval between doses and 60–82-fold for those with a 3–8-y interval. Titer distributions after the booster dose were comparable in the two studies. These results indicate that 2-dose HPV vaccination schedules with an interval of several years could be used for pre-adolescents. Intervals longer than 6 months may facilitate logistics for immunization programs and could be useful during periods of vaccine shortage or as a transition while the effectiveness of a one-dose schedule is being evaluated.
first_indexed 2024-03-11T11:58:09Z
format Article
id doaj.art-c9f5139cb67d4e3bbb7ffac62647c981
institution Directory Open Access Journal
issn 2164-5515
2164-554X
language English
last_indexed 2024-03-11T11:58:09Z
publishDate 2019-08-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj.art-c9f5139cb67d4e3bbb7ffac62647c9812023-11-08T11:55:19ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2019-08-01157-81980198510.1080/21645515.2019.16052781605278Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trialsVladimir Gilca0Chantal Sauvageau1Gitika Panicker2Gaston De Serres3John Schiller4Manale Ouakki5Elisabeth R. Unger6Quebec Public Health InstituteQuebec Public Health InstituteCenters for Disease Control and PreventionQuebec Public Health InstituteNational Cancer InstituteQuebec Public Health InstituteCenters for Disease Control and PreventionThe objective of this analysis was to compare the anti-HPV GMTs and their distribution after a 6-month or a 3–8 -y interval between two HPV vaccine doses. The results from two clinical trials, conducted by the same team in the same region, with serological assays performed at the same laboratory using the same ELISA methodology were compared. In the first study, 173 9–10-y-old girls and boys received two doses of 9vHPV vaccine at a 6-month interval; in the second study, 31 girls vaccinated with one dose of 4vHPV at the age of 9–14 y received a dose of 9vHPV 3–8 y later (mean 5.4 y). In both studies, blood samples were collected before and 1 month post second dose. Despite large differences in the time since the first dose, all subjects (100%) were seropositive to the common 4 HPV types (6, 11, 16 and 18) to both vaccines, with comparable GMTs and titer distributions before the second dose. One month post second dose, the GMTs increased 40–91-fold for those with a 6-month interval between doses and 60–82-fold for those with a 3–8-y interval. Titer distributions after the booster dose were comparable in the two studies. These results indicate that 2-dose HPV vaccination schedules with an interval of several years could be used for pre-adolescents. Intervals longer than 6 months may facilitate logistics for immunization programs and could be useful during periods of vaccine shortage or as a transition while the effectiveness of a one-dose schedule is being evaluated.http://dx.doi.org/10.1080/21645515.2019.1605278hpv vaccineone dosetwo doseslong intervals
spellingShingle Vladimir Gilca
Chantal Sauvageau
Gitika Panicker
Gaston De Serres
John Schiller
Manale Ouakki
Elisabeth R. Unger
Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials
Human Vaccines & Immunotherapeutics
hpv vaccine
one dose
two doses
long intervals
title Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials
title_full Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials
title_fullStr Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials
title_full_unstemmed Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials
title_short Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials
title_sort long intervals between two doses of hpv vaccines and magnitude of the immune response a post hoc analysis of two clinical trials
topic hpv vaccine
one dose
two doses
long intervals
url http://dx.doi.org/10.1080/21645515.2019.1605278
work_keys_str_mv AT vladimirgilca longintervalsbetweentwodosesofhpvvaccinesandmagnitudeoftheimmuneresponseaposthocanalysisoftwoclinicaltrials
AT chantalsauvageau longintervalsbetweentwodosesofhpvvaccinesandmagnitudeoftheimmuneresponseaposthocanalysisoftwoclinicaltrials
AT gitikapanicker longintervalsbetweentwodosesofhpvvaccinesandmagnitudeoftheimmuneresponseaposthocanalysisoftwoclinicaltrials
AT gastondeserres longintervalsbetweentwodosesofhpvvaccinesandmagnitudeoftheimmuneresponseaposthocanalysisoftwoclinicaltrials
AT johnschiller longintervalsbetweentwodosesofhpvvaccinesandmagnitudeoftheimmuneresponseaposthocanalysisoftwoclinicaltrials
AT manaleouakki longintervalsbetweentwodosesofhpvvaccinesandmagnitudeoftheimmuneresponseaposthocanalysisoftwoclinicaltrials
AT elisabethrunger longintervalsbetweentwodosesofhpvvaccinesandmagnitudeoftheimmuneresponseaposthocanalysisoftwoclinicaltrials